SEC Form 4 · accession 0001613377-16-000037
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David R Strayer
Officer — Chief Science/Medical Officer
Period of report
Jul 29, 2016
Accepted (ET)
Jul 29, 2016 · 1:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive RightsF1 | $0.00 | Jul 29, 2016 | A | 20,479 | A | Jan 31, 2017 | Jan 31, 2017 | Common Stock | 20,479 | 20,479 | D |
Explanation of responses
- F1Issued pursuant to the Hemispherx Biopharma Inc 2016 voluntary incentive stock award plan. Pursuant to the plan, the reporting person has elected to withhold a portion of their salary in exchange for the incentive right. The incentive right grants the reporting person the right to receive a number of shares of common stock based upon the market price on the day prior to election. The incentive right automatically converts into common stock on the date exercisable. The plan is described in the Issuer's annual 10K report for the year ended 12/31/15.